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T he hemodynamic response to ventricular tachycardia is an important determinant of prognosis.’ Many 
factors determine the hemodynamic response to ventricu- 
lar tachycardia, including (1) the rate of the ventricular 
tachycardia,2*3 (2) systolic and diastolic ventricular func- 
tion,4J and (3) the neurohumoral response to the arrhyth- 
mia.6v7 Antiarrhythmic drugs such as quinidine and 
amiodarone may either improve hemodynamics during 
ventricular tachycardia by slowing the rate of the tachy- 
cardia, or may impair the hemodynamic response to ven- 
tricular tachycardia by decreasing ventricular contractili- 
ty, blunting the neurohumoral response to the tachycar- 
dia, or by causing vasodilation.8-14 No prior studies have 
evaluated the effect of antiarrhythmic drugs on the he- 
modynamic response to ventricular tachycardia indepen- 
dent of their effects on the rate of the tachycardia. The 
objective of this study was to determine the relative ef- 
fects of quinidine and amiodarone on the blood pressure 
(BP) response to rapid ventricular pacing in humans. 
Previous studies have demonstrated that the BP response 
during ventricular tachycardia and during ventricular 
pacing are similar.2 Therefore, in this study ventricular 
pacing was used to assess the effects of antiarrhythmic 
drugs on the BP response independent of heart rate. 
The subjects of this study were 9patients (8 men and 
I woman, mean age 6.2 f 7 years) who had inducible 
sustained monomorphic ventricular tachycardia during 
electrophysiologic testing and who underwent electro- 
pharmacologic testing with both quinidine and amioda- 
rone. The indication for electrophysiologic testing was 
aborted sudden death in 2patients, syncope in 6patients, 
and nonsustained ventricular tachycardia in I patient. 
Each patient had coronary artery disease and a history 
of a prior myocardial infarction. The mean left ventricu- 
lar ejection fraction was 0.33 f 0.11. Each of the 9 
patients was clinically stable at the time of their initial 
electraphysiology test and throughout theperiodof eval- 
uation. No patient had angina1 symptoms, a history of a 
myocardial infarction within the prior 3 months, or con- 
gestive heart failure requiring adjustment of their medi- 
cal regimen. Six patients were being treated with digox- 
in, 5 with diuretics, 4 with an angiotensin-converting 
enzyme inhibitor, and I patient with a calcium antago- 
nist. The dose of calcium antagonists and angiotensin- 
converting enzyme inhibitors was kept constant through- 
out the period of evaluation. The dose of digoxin was 
reduced by 50% at the time of initiation of quinidine and 
amiodarone therapy. 
Electrophysiologv tests were performed in the fasting 
state >5 half-lives after discontinuation of all antiar- 
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rhythmic drugs and /3 blockers. Each patient gave in- 
formed consent. Quadripolar electrode catheters were 
inserted into a femoral vein and positioned at the high 
right atrium, across the tricuspid valve to record a His 
bundle electrogram, and at the apex of the right ventri- 
cle. A 5Fr cannula was inserted into a femoral artery for 
BP monitoring. Leads VI, I and III, the intracardiac 
electrograms, and BP were recorded at a paper speed of 
10 or 25 mm/s using a Siemans-Elema Mingograph 7 
recorder. 
All patients also underwent electrophysiologic test- 
ing after treatment with quinidine and amiodarone. Fol- 
low-up testing during quinidine therapy was performed 
248 hours after initiation of treatment with quinidine 
gluconate at a dose of 486 to 648 mg 3 times a day. The 
follow-up electrophysiology test was performed <2 
hours before the next scheduled dose. The mean plasma 
quinidine concentration at the time offollow-up electro- 
physiologic testing was 3.2 f 1.0 mg/liter (range 2.2 to 
4.3 mg/liter). Each patient still had inducible sustained 
monomorphic ventricular tachycardia during treatment 
with quinidine and was then treated with amiodarone. 
Follow-up electrophysiologic testing during amiodarone 
therapy was performed 9 to 10 days after initiation of 
treatment with amiodarone at a dose of 1,800 mg/day in 
3 divided doses. 
The pacing protocol was performed in each patient 
after completion of the clinically indicatedportion of the 
electrophysiology test. Pacing was performed at the right 
ventricular apex at cycle lengths of 600, 500, 400, 350, 
300,280 and 260 ms. Ventricular pacing was performed 
at e.ach cycle length for 30 to 40 seconds or until the 
patient became presyncopal. The minimal duration of 
pacing at each cycle length was 20 seconds. The sequence 
of cycle lengths at which pacing was performed was 
randomized. If the patient’s systolic BP was <40 mm Hg 
at a given cycle length, pacing at shorter cycle lengths 
was not performed. Between pacing at each cycle length, 
the patient was allowed to recover for 25 minutes or 
until mean BP returned to within 5 mm Hg of the base- 
line mean BP. No patient developed angina or ischemic 
ST changes during pacing. 
At each pacing cycle length the systolic, diastolic and 
mean BPS were measured after 30 seconds of pacing or at 
thepoint at which the patient becamepresyncopal (mini- 
mum of 20 seconds). BP was determined by averaging 
the BP response during 4 to 6 beats. Thirty seconds was 
selected because previous studies have demonstrated 
that the initial abrupt decrease in BP during rapid ven- 
tricular pacing is followed by an increase in BP. Stabili- 
zation of the BP is generally achieved within 30 seconds 
of the onset of rapid ventricular pacing.6,7 To confirm 
stabilization of BP within 30 seconds of pacing, BP was 
compared 30 and 40 seconds after onset of pacing in each 
patient at I or more cycle lengths between 300 and 400 
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TABLE I Systolic Blood Pressure During Ventricular Pacing 
Cycle Length (ms) Baseline Quinldine Amiodarone p Value 
Sinus rhythm 138 2 28 124 2 28 133 k 24 0.19 
600 128 2 27 120 + 31 129 + 26 0.33 
500 131 -c 26 121 2 26 123 2 29 0.29 
400 120 2 17 109 2 28 111 * 35 0.33 
350 97 + 18 81 t 29 79 t 34 0.05* 
300 65 ? 14 55 -t 23 56 2 28 0.27 
280 52 k 9 442 14 42 r 15 0.03t 
260 39 -t 7 40 I 8 39 r 16 0.28 
*p = 0.1 baselinevenusquinldine; p = 0.04 basellnevenus amcdarone; p = 0.18 
qulnidlne verws amlodarone. 
tp = 0.05 baselme versus quinidme; p = 0.04 baseline versus amiodarone, p = 
0.18 quinidine versus amiodarone. 
, 
ms. Neither the systolic nor the diastolic BP differed at 
30 and 40 seconds of pacing (p >0.2). 
The effects of quinidine and amiodarone on BP dur- 
ing ventricular pacing were evaluated in 2 ways. In the 
first analysis, the systolic and mean BP at each paced 
cycle length in the baseline state and during therapy with 
quinidine and amiodarone were compared using a re- 
peated-measures analysis of variance and paired t tests. 
To determine the independent effects of cycle length and 
drug regimen on the BP response to ventricular pacing, a 
repeated-measures analysis of variance for 2 factors, 
both of which are repeated, was also performed. The 
second method of analysis involved modeling the rela- 
tion between BP and the pacing rate via polynomial 
regressions, and comparing the estimated coefficients for 
the model of this relation under the 3 conditions. For 
each of the 2 variables, mean BP and systolic BP, models 
relating these variables to heart rate were developed as 
follows: First, we investigated which regression model - 
linear, quadratic or cubic - adequately fit the data for 
each patient andcondition separately. Based on the coef- 
TABLE II Mean Blood Pressure During Ventricular Pacing 
Cycle Length (ms) Baseline Quinidine Amiodarone p Value 
Sinus rhythm 89 2 13 81 -t 13 84 + 10 0.08 
600 87 t 15 79 r 14 86 2 13 0.06 
500 87 + 15 80 k 12 84 + 13 0.19 
400 842 13 74 ?z 16 77 -+ 20 0.19 
350 69 -t 13 58 2 18 56 e 21 0.04* 
I 300 50 + 7 43 -t 13 41 + 16 0.08 
I 280 41 2 7 35k 11 36 k 9 0.14 
I 260 31 r4 28 t 6 30 ‘- 9 0.24 
*p = 0.03 baseline versus qulnidlne; p = 0.05 baseline versus amicdarone; p = 
0.75 quinidine versus amiodarone. 
ftcients of determination (r2), it was concluded that a 
linear model explained a sufficient proportion of the 
variation for both mean BP and systolic BP (average ? 
was 0.86 and 0.89 for mean BP and systolic BP, respec- 
tively). Next, using the estimated intercept and slope 
from these linear regressions for each patient and condi- 
tion, a repeated-measures analysis of variance and 
paired t tests were computed to assess whether differ- 
ences among the 3 conditions exist. A p value KO.05 was 
considered significant. 
Table I summarizes the effect of pacing on systolic 
BP in the baseline state and during therapy with quini- 
dine and amiodarone. Systolic BP was no different dur- 
ing quinidine and amiodarone therapy than under base- 
line conditions at most paced cycle lengths. However, at 
a paced cycle length of 350 ms, systolic BP was lower 
during amiodarone therapy than in the baseline state, 
and at a paced cycle length of 280 ms, systolic BP was 
lower during quinidine and amiodarone therapy than in 
the baseline state. An analysis of variance for 2 repeated 
factors (drug regimen and cycle length) demonstrated 
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length on the systolic BP response to pacing (p <O.OOl) 
but that there was no effect of drug regimen on the 
systolic BP response to ventricular pacing (p = 0.08). 
Table II describes the effect of pacing on the mean 
BP. The mean BP was no different during quinidine and 
amiodarone therapy than under baseline conditions at 
all paced cycle lengths except at a cycle length of 350 ms. 
During ventricular pacing at 350 ms, the mean BP was 
lower during both quinidine and amiodarone therapy 
than in the baseline state. An analysis of variance for 2 
repeatedfactors (drug regimen and cycle length) demon- 
strated that there was a significant independent effect of 
cycle length on the mean BP response to pacing (p 
<O.OOl), but that there was no effect of drug regimen on 
the mean BP response to ventricular pacing (p = 0.1 I). 
Neither the y-intercept nor the slope of the inverse 
linear relation between heart rate and systolic BP were 
different in the baseline state than during quinidine and 
amiodarone therapy (207 f 40 us 194 f 45 us 208 f 41 
mm Hg, p = 0.5 and -0.7 f 0.2 vs -0.7 f 0.2 vs -0.8 f 
0.2, p = 0.4, respectively: Figure 1). Similarly, neither 
the y-intercept nor the slope of the inverse linear relation 
between heart rate and mean BP were different in the 
baseline state than during quinidine and amiodarone 
therapy (133 f 26 us 120 f 21 us 132 f 18 mm Hg, 
p = 0.14 and -0.4 f 0.1 us -0.4 f 0.1 us -0.4 f 0.1, 
p = 0.09, respectively; Figure 2). 
The main finding of this study is that quinidine and 
amiodarone do not significantly alter the BP response to 
rapid ventricular pacing. At almost all paced cycle 
lengths, systolic and mean BP were no different during 
therapy with quinidine and amiodarone than in the base- 
line state. Furthermore, the drug regimen did not have an 
independent effect on the BP response to pacing, and the 
slope and y-intercept of the linear relation between systol- 
ic and mean BP and heart rate were not altered by quini- 
dine and amiodarone therapy. These findings suggest 
that the predominant mechanism by which quinidine and 
amiodarone influence BP response to ventricular tachy- 
cardia is by altering the rate of the tachycardia. 
There are several mechanisms by which quinidine and 
amiodarone may influence BP response to pacing. First, 
both amiodarone and quinidine have been shown to im- 
pair myocardial contractility in experimental models.9 
Second, both agents may alter autonomic tone during 
ventricular tachycardia. Previous studies have demon- 
strated that recovery from the initial decrease in BP at the 
onset of ventricular tachycardia depends on both cy-adre- 
nergic vasoconstriction and /3-adrenergic augmentation 
of contraction and relaxation.6 Amiodarone, a noncom- 
petitive ,L? blocker, may therefore blunt the Badrenergic 
augmentation of contraction and relaxation and quini- 
dine may cause cy-adrenergic blockade of both venous and 
arterial vascular beds.rO Third, both quinidine and amio- 
darone have been demonstrated to be direct vasodilators 
capable of reducing peripheral vascular tone. l I>12 
Despite the presence of several mechanisms by which 
quinidine and amiodarone may influence hemodynamics, 
the results of this study demonstrate that quinidine and 
amiodarone do not have a major effect on the BP re- 
sponse to pacing. At nearly all paced cycle lengths there 
was no difference in BP during therapy with quinidine 
and amiodarone compared with the baseline state. Fur- 
thermore, the drug regimen did not have an independent 
effect on BP, and the overall linear relation between pac- 
ing rate and BP was not altered after quinidine and amio- 
darone therapy. These findings are consistent with the 
findings of previous clinical studies demonstrating that 
the hemodynamic effects of quinidine and amiodarone 
are slight and that these agents generally are well tolerat- 
ed clinically.13J4 
A limitation to this study is that the 3 electrophysiol- 
ogy tests that were performed in the baseline state and 
during quinidine and amiodarone therapy were per- 
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formed on separate days. Factors related to the duration 
of hospitalization, e.g., the degree of physical decondi- 
tioning or the patient’s emotional status, were not con- 
trolled and may have influenced BP response to pacing. A 
second limitation is that a complete evaluation of the 
patient’s hemodynamic status was not performed. Al- 
though no difference was found in the BP response to 
pacing, it is possible that the cardiac output or other 
hemodynamic variables may have been altered by the 
antiarrhythmic agents that were studied. A third limita- 
tion is that the BP was evaluated while patients were in 
the supine position. Quinidine or amiodarone may have 
affected the patient’s BP response to rapid ventricular 
pacing in the upright position. 
Potential adverse clinical effects of antiarrhythmic 
agents include proarrhythmia, and the exacerbation of 
congestive heart failure.8 Recently, several investigators 
have suggested that antiarrhythmic agents may also have 
an adverse clinical effect by aggravating the hemody- 
namic response to ventricular tachycardia’ 5 - namely, a 
patient with hemodynamically stable ventricular tachy- 
cardia in the absence of antiarrhythmic therapy may 
have hemodynamically unstable ventricular tachycardia 
during antiarrhythmic therapy. The results of this study 
suggest that this third type of adverse clinical effect is not 
a prominent factor for quinidine and amiodarone, and 
suggest that the effect of these antiarrhythmic agents on 
BP response to ventricular tachycardia results predomi- 
nantly from their effect on the ventricular tachycardia 
rate. 
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Regression of Left Ventricular Hypertrophy in Systemic Hypertension 
with Beta Blockers (Propranolol, Atenolol, Metoprolol, Pindolol and 
Celiprolol) 
Gregory P. Vyssoulis, MD, Eva A. Karpanou, MD, Christos E. Pitsavos, MD, 
Athanasios A. Paleologos, MD, and Pavlos K. Toutouzas, MD 
L eft ventricular (LV) hypertrophy is frequently associ- ated with systemic arterial hypertension and is a 
recognized, independent risk factor for coronary artery 
disease.1*2 Reduction of LV hypertrophy is thus a desir- 
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able goal in the treatment of high blood pressure (BP), 
but not all antihypertensive drugs accomplish this.3 Beta- 
adrenergic blocking agents have not been shown to re- 
verse LV hypertrophy in patients with essential hyperten- 
sion, but few comparative and quantitative studies with 
different j3 blockers have been reported.4 This report con- 
cerns a study of the effects on echocardiographic LV 
hypertrophy indexes in 145 hypertensive patients treated 
with 5 different /3-blocking drugs. 
TABLE I Characteristics of Patients in Each Treatment Group 
Propranolol Atenolol Metroprolol Pindolol Celiprolol 
Age (year) 51 k 9 48 + 10 51+ 11 51 5 12 47 + 11 
Patients (men/women) 23 (17/6) 21 (16/5) 18 (1117) 35 (18/17) 48 (27/21) 
Duration of hypertension (year) 6k4 5k4 4*3 6?5 524 
Doses at end study (mg) 60 100 100 15 200 
Duration of treatment (weeks) 29% 11 282 11 26 k 10 31 * 12 27 c 10 
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